China’s First mRNA-Based In Vivo CAR-T Candidate! Medicilon Supports Regenelead RGL-208 IND Approval
November 3 — RGL-208 Injection, a dual-target in vivo CAR-T candidate independently developed by Regenelead, has received implied clinical trial approval from the NMPA. It is intended for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. RGL-208 marks China’s first mRNA in vivo CAR-T product to enter clinical development, as well as Regenelead’s first in vivo […]
Medicilon and China Pharmaceutical University Forge Industry-University Research Collaboration on Novel Conjugate Therapeutics to Empower New Drug Innovation
November 5 marks the 7th anniversary of Medicilon’s listing and the 90th anniversary of the founding of China Pharmaceutical University (CPU). Recently, Medicilon and the School of Life Science and Technology of CPU officially signed an industry-university research cooperation agreement. The two parties will carry out in depth collaboration in novel conjugate therapeutics, bridging the […]
7th Anniversary Q&A 7: Seven Years Listed, Honors Without Number: Why Does Medicilon Keep the Trust of the Industry and Its Clients?
Seven years after listing, Medicilon has kept building depth as innovative drug sector gathered pace. Over those seven years, the honors that have come its way — from the choices clients make to recognition from the industry, from technical breakthroughs to compliant delivery — are not isolated labels but long-term proof of one capability: one-stop […]
7th Anniversary Q&A 6: One IND Approval Every Four Days on Average: How Does Medicilon Balance R&D Speed and Quality?
In the seven years since its IPO, Medicilon has helped bring nearly 700 IND applications to clinical approval — around 100 a year, which works out to one new drug crossing the IND threshold and entering the clinic on Medicilon’s platform every four days or so.Racing timelines on one side, tightening global compliance on the […]
Medicilon Debuts at CIIE, Connecting the World
Medicilon Debuts at CIIE Medicilon showcased its comprehensive R&D services at the 9th China International Import Expo (CIIE) in Shanghai, held from November 5-10, 2026. Featured in the Pudong New Area’s service trade pavilion, Medicilon highlighted its drug discovery, pharmaceutical, and preclinical research capabilities, aiming to expand global innovation partnerships. Medicilon’s presence underscored the growing […]
Medicilon TPD & RIPTAC R&D Service Platform

Fill out the form below to download this content.
Nonclinical Toxicology Services (GLP and non-GLP)
Medicilon offers comprehensive toxicology study services designed to assess the safety profile and potential risks of pharmaceutical compounds. Our expert team collaborates closely with clients to tailor studies according to regulatory requirements and project-specific needs. Our state-of-the-art facilities, advanced platform, experienced scientists, and commitment to quality ensure that clients receive high quality, reliable, and regulatory-compliant […]
Medicilon Nonclinical Toxicology Services

Fill out the form below to download this content.
Medicilon NAMs Drug Service Platform

Fill out the form below to download this content.
Medicilon – From Target to IND, Accelerating New Drug R&D

Fill out the form below to download this content.